FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3037977086> ?p ?o ?g. }

• W3037977086 endingPage "541" @default.
• W3037977086 startingPage "531" @default.
• W3037977086 abstract "We conducted a randomised phase II study to determine the optimal dose and schedule of melphalan, prednisone, and bortezomib (MPB) (jRCTs031180097). Transplant-ineligible untreated multiple myeloma patients were randomised to Arm A (twice weekly bortezomib in one six-week cycle followed by eight five-week cycles of four times once weekly bortezomib with melphalan and prednisolone on days 1-4) or Arm B (nine four-week cycles of three times once weekly bortezomib with melphalan and prednisolone on days 1-4). The primary end-point was complete response (CR) rate. Of 91 patients randomised to two arms, 88 were eligible. The median cumulative bortezomib doses were 45·8 and 35·1 mg/m2 , CR rate was 18·6% [95% confidence interval (CI) 8·4-33·4] and 6·7% (95% CI 1·4-18·3), and the median progression-free survival (PFS) was 2·5 and 1·4 years in Arms A and B [hazard ratio (HR) 1·93 (95% CI 1·09-3·42)], respectively. Frequent grade ≥3 haematologic toxicities in Arms A and B were neutropenia (64·4% vs. 28·3%) and thrombocytopenia (35·6% vs. 10·9%). Grade 2/3 peripheral neuropathy was observed in 24·4/2·2% in Arm A and 8·7/0% in Arm B. In conclusion, Arm A was the more promising regimen, suggesting that the twice weekly schedule of bortezomib in the first cycle and higher cumulative dose of both bortezomib and melphalan influences the efficacy of modified MPB." @default.
• W3037977086 created "2020-07-02" @default.
• W3037977086 creator A5009149908 @default.
• W3037977086 creator A5015436878 @default.
• W3037977086 creator A5020149985 @default.
• W3037977086 creator A5024413745 @default.
• W3037977086 creator A5034245076 @default.
• W3037977086 creator A5034798001 @default.
• W3037977086 creator A5036112859 @default.
• W3037977086 creator A5037105339 @default.
• W3037977086 creator A5041701016 @default.
• W3037977086 creator A5045993454 @default.
• W3037977086 creator A5046158861 @default.
• W3037977086 creator A5049465924 @default.
• W3037977086 creator A5052281366 @default.
• W3037977086 creator A5055192416 @default.
• W3037977086 creator A5056681640 @default.
• W3037977086 creator A5059948213 @default.
• W3037977086 creator A5060866250 @default.
• W3037977086 creator A5064953907 @default.
• W3037977086 creator A5068935539 @default.
• W3037977086 creator A5072772886 @default.
• W3037977086 creator A5075358038 @default.
• W3037977086 creator A5078852881 @default.
• W3037977086 creator A5084289729 @default.
• W3037977086 creator A5088060397 @default.
• W3037977086 creator A5088100950 @default.
• W3037977086 date "2020-06-24" @default.
• W3037977086 modified "2023-10-17" @default.
• W3037977086 title "Randomised phase II study to optimise melphalan, prednisolone, and bortezomib in untreated multiple myeloma (JCOG1105)" @default.
• W3037977086 cites W1608379611 @default.
• W3037977086 cites W1978436046 @default.
• W3037977086 cites W1985864219 @default.
• W3037977086 cites W1994351520 @default.
• W3037977086 cites W2035310226 @default.
• W3037977086 cites W2044436186 @default.
• W3037977086 cites W2070790769 @default.
• W3037977086 cites W2096207943 @default.
• W3037977086 cites W2102331162 @default.
• W3037977086 cites W2120780398 @default.
• W3037977086 cites W2128116151 @default.
• W3037977086 cites W2134902298 @default.
• W3037977086 cites W2137245721 @default.
• W3037977086 cites W2164807675 @default.
• W3037977086 cites W2201190784 @default.
• W3037977086 cites W2318069817 @default.
• W3037977086 cites W2425909334 @default.
• W3037977086 cites W2528329272 @default.
• W3037977086 cites W2530085796 @default.
• W3037977086 cites W2567188480 @default.
• W3037977086 cites W2772566228 @default.
• W3037977086 cites W2802890120 @default.
• W3037977086 cites W2947874495 @default.
• W3037977086 cites W2955881672 @default.
• W3037977086 cites W2996752315 @default.
• W3037977086 doi "https://doi.org/10.1111/bjh.16878" @default.
• W3037977086 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7891591" @default.
• W3037977086 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32583431" @default.
• W3037977086 hasPublicationYear "2020" @default.
• W3037977086 type Work @default.
• W3037977086 sameAs 3037977086 @default.
• W3037977086 citedByCount "9" @default.
• W3037977086 countsByYear W30379770862021 @default.
• W3037977086 countsByYear W30379770862022 @default.
• W3037977086 countsByYear W30379770862023 @default.
• W3037977086 crossrefType "journal-article" @default.
• W3037977086 hasAuthorship W3037977086A5009149908 @default.
• W3037977086 hasAuthorship W3037977086A5015436878 @default.
• W3037977086 hasAuthorship W3037977086A5020149985 @default.
• W3037977086 hasAuthorship W3037977086A5024413745 @default.
• W3037977086 hasAuthorship W3037977086A5034245076 @default.
• W3037977086 hasAuthorship W3037977086A5034798001 @default.
• W3037977086 hasAuthorship W3037977086A5036112859 @default.
• W3037977086 hasAuthorship W3037977086A5037105339 @default.
• W3037977086 hasAuthorship W3037977086A5041701016 @default.
• W3037977086 hasAuthorship W3037977086A5045993454 @default.
• W3037977086 hasAuthorship W3037977086A5046158861 @default.
• W3037977086 hasAuthorship W3037977086A5049465924 @default.
• W3037977086 hasAuthorship W3037977086A5052281366 @default.
• W3037977086 hasAuthorship W3037977086A5055192416 @default.
• W3037977086 hasAuthorship W3037977086A5056681640 @default.
• W3037977086 hasAuthorship W3037977086A5059948213 @default.
• W3037977086 hasAuthorship W3037977086A5060866250 @default.
• W3037977086 hasAuthorship W3037977086A5064953907 @default.
• W3037977086 hasAuthorship W3037977086A5068935539 @default.
• W3037977086 hasAuthorship W3037977086A5072772886 @default.
• W3037977086 hasAuthorship W3037977086A5075358038 @default.
• W3037977086 hasAuthorship W3037977086A5078852881 @default.
• W3037977086 hasAuthorship W3037977086A5084289729 @default.
• W3037977086 hasAuthorship W3037977086A5088060397 @default.
• W3037977086 hasAuthorship W3037977086A5088100950 @default.
• W3037977086 hasBestOaLocation W30379770861 @default.
• W3037977086 hasConcept C126322002 @default.
• W3037977086 hasConcept C143998085 @default.
• W3037977086 hasConcept C2776063141 @default.
• W3037977086 hasConcept C2776364478 @default.
• W3037977086 hasConcept C2776715498 @default.
• W3037977086 hasConcept C2777478702 @default.

• next